A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
Seagen Inc.
Astellas Pharma Inc
Servier
Sotio Biotech Inc.
Rondo Therapeutics
Daiichi Sankyo
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sutro Biopharma, Inc.
Neonc Technologies, Inc.
Merck Sharp & Dohme LLC
Shanghai Henlius Biotech
Seagen Inc.
Qurient Co., Ltd.
AstraZeneca
Seagen Inc.
Tizona Therapeutics, Inc
Nouscom SRL
Takeda
RemeGen Co., Ltd.
ImmunityBio, Inc.
Amgen
Linnaeus Therapeutics, Inc.
Inhibrx Biosciences, Inc
Suzhou Transcenta Therapeutics Co., Ltd.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hanmi Pharmaceutical Company Limited
Sanofi
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
Medicenna Therapeutics, Inc.
OncoC4, Inc.
Aprea Therapeutics
Imugene Limited
MacroGenics
Merus B.V.
Carisma Therapeutics Inc
NextCure, Inc.
Celularity Incorporated
Highlight Therapeutics
Vincerx Pharma, Inc.
Inhibrx Biosciences, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
ADC Therapeutics S.A.
Merck Sharp & Dohme LLC
Coherus Oncology, Inc.